Raymond James & Associates Sells 23,748 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Raymond James & Associates lowered its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) by 15.8% in the fourth quarter, Holdings Channel reports. The firm owned 126,442 shares of the biopharmaceutical company’s stock after selling 23,748 shares during the quarter. Raymond James & Associates’ holdings in TG Therapeutics were worth $2,160,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in TGTX. PNC Financial Services Group Inc. grew its position in TG Therapeutics by 131.7% in the third quarter. PNC Financial Services Group Inc. now owns 3,543 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 2,014 shares in the last quarter. Macquarie Group Ltd. grew its position in shares of TG Therapeutics by 102.3% in the 2nd quarter. Macquarie Group Ltd. now owns 10,190 shares of the biopharmaceutical company’s stock valued at $43,000 after acquiring an additional 5,152 shares during the period. Coppell Advisory Solutions LLC bought a new position in shares of TG Therapeutics in the 2nd quarter valued at about $46,000. Lazard Asset Management LLC bought a new position in shares of TG Therapeutics in the 3rd quarter valued at about $56,000. Finally, NBC Securities Inc. bought a new position in shares of TG Therapeutics in the 3rd quarter valued at about $58,000. Institutional investors own 58.58% of the company’s stock.

TG Therapeutics Price Performance

Shares of TG Therapeutics stock opened at $14.00 on Wednesday. TG Therapeutics, Inc. has a twelve month low of $6.46 and a twelve month high of $35.67. The company has a quick ratio of 5.18, a current ratio of 5.92 and a debt-to-equity ratio of 0.62. The company has a 50-day simple moving average of $15.15 and a two-hundred day simple moving average of $13.87. The stock has a market capitalization of $2.16 billion, a price-to-earnings ratio of 700.35 and a beta of 2.30.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.03. TG Therapeutics had a net margin of 5.42% and a return on equity of 12.89%. The business had revenue of $43.97 million during the quarter, compared to analysts’ expectations of $40.06 million. During the same quarter in the previous year, the company earned ($0.39) EPS. Analysts forecast that TG Therapeutics, Inc. will post -0.12 EPS for the current year.

Insider Buying and Selling at TG Therapeutics

In other TG Therapeutics news, Director Laurence N. Charney sold 22,000 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $15.97, for a total value of $351,340.00. Following the transaction, the director now directly owns 215,229 shares of the company’s stock, valued at approximately $3,437,207.13. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 9.20% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. The Goldman Sachs Group lifted their price objective on shares of TG Therapeutics from $12.00 to $13.00 and gave the company a “neutral” rating in a research report on Thursday, February 29th. StockNews.com cut shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, February 24th. B. Riley raised their target price on shares of TG Therapeutics from $24.00 to $29.00 and gave the stock a “buy” rating in a research note on Monday, February 5th. Finally, HC Wainwright restated a “buy” rating and set a $45.00 target price on shares of TG Therapeutics in a research note on Wednesday, February 28th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $26.17.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.